US Stock MarketDetailed Quotes

LUMO Lumos Pharma

Watchlist
  • 1.800
  • +0.260+16.88%
Close Jul 26 16:00 ET
  • 1.720
  • -0.080-4.44%
Post 17:51 ET
14.61MMarket Cap-393P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Jun 4 08:05
    NEWS
    $Lumos Pharma(LUMO.US)$
    Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
    Lumos Pharma presented new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 meeting. The data reveals that oral LUM-201 significantly increased growth hormone (GH) secretion in children with moderate Pediatric Growth Hormone Deficiency (PGHD) over six months. The treatment restored GH levels to near-normal compared to healthy children, with lower GH exposure than tradit...
    Trytosaveabit
    Trytosaveabit
    May 14 15:16
    Update
    $Lumos Pharma(LUMO.US)$ Reuters· just
    Lumos Pharma Inc: Outcome From End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial
    Trytosaveabit
    Trytosaveabit
    Apr 18 16:03
    Let’s see what good stuff comes from these?
    $Lumos Pharma(LUMO.US)$ Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
    AUSTIN, TX, April 18, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented...
    Trytosaveabit
    Trytosaveabit
    Mar 20 07:09
    News
    $Lumos Pharma(LUMO.US)$ Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042
    Trytosaveabit
    Trytosaveabit
    Mar 8 06:55
    Update
    $Lumos Pharma(LUMO.US)$ © Reuters. Lumos Pharma (ticker: NASDAQ:LUMO) has announced promising top-line results from its OraGrowtH210 and OraGrowtH212 trials for LUM-201, highlighting its potential as an oral treatment for pediatric growth hormone deficiency (PGHD). The company detailed plans for future trials and regulatory discussions during its recent earnings call. With $36.1 million in cash at the end of 2023, Lumos Pharma is funded through Q3 2024 and is actively exploring partnership...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg
Concept Top Gainers Yesterday
Top Gainers Yesterday
Intraday+0.11%